|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||60.65 - 60.65|
|52-week range||60.65 - 60.65|
|Beta (5Y monthly)||1.45|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
VRTX vs. PRTA: Which Stock Is the Better Value Option?
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.